Western Pacific Region (WPR)
These guidelines aim to standardize cervical cancer screening in China and reduce the incidence and mortality rate of invasive cervical cancer. The first part outlines the primary screening strategies for cervical cancer.
In this revision, the main changes include new information on: i) Guidance on primary cervical cancer prevention by HPV vaccination ii) Guidance on the use of HPV testing as a stand-alone test or as part of co-testing with cytology for primary screening iii) WHO 2020 nomenclature vi) Details of different available HPV tests
This revised edition of our guidelines incorporates the latest advancements, emphasizing the importance of integrating HPV testing as a primary screening modality. The combination of liquid-based cytology and HPV DNA testing represents a significant advancement in our screening strategy
This resource outlines changes to the NCSP Guidelines relevant to primary care, effective from 14 April 2025 • MagicAPP now hosts the National Cervical Screening Program Guidelines, creating a more user-friendly experience
• New chapter ‘Cervical Screening in Clinical Practice’ (chapter 5) brings together information relevant for General Practice in one place
The National Cervical Screening Program Guidelines (NCSP Guidelines) outline the National Cervical Screening Program’s (NCSP) risk-based approach to clinical pathway management of cervical screening participants.
The National Cervical Screening Program Guidelines (NCSP Guidelines) outline the National Cervical Screening Program’s (NCSP) risk-based approach to clinical pathway management of cervical screening participants.